Medical experts are focused on helping the immune system topple mesothelioma. Immune checkpoint inhibitors are one method.
Dendritic cell therapy is another encouraging type of mesothelioma immunotherapy.
A study in the United Kingdom published in Vaccines details a 29-patient analysis of dendritic cell therapy. The median survival was 27 months, which is far better than regular chemotherapy treatment and even immune checkpoint inhibitors. The two-year survival was 55% and five-year survival was 20%, which are both superior to traditional mesothelioma therapies.
Dendritic cell therapy involves adding dendritic cells to the patient’s body. These cells present antigens that deliver fingerprints to the immune system’s T-cells. These fingerprints allow T-cells to seek and destroy cancer cells.
“Dendritic cells are among the most potent antigen-presenting immune cells to activate these T-cells,” the authors wrote.
Why Dendritic Cell Therapy Works for Mesothelioma
Mesothelioma is an immune-suppressing cancer due to specific proteins, such as PD-L1, B7 and vascular endothelial growth factor. The first two are checkpoint inhibitors, treated with immunotherapy drugs Opdivo and Yervoy, and the last is a growth vessel for cancer cells.
All of these prevent the maturation of dendritic cells, which aren’t activated properly. The immune system needs dendritic cells to act as a middle man between the cancer cells and T-cells.
Dendritic cells are part of the process for the therapy ONCOS-102 for mesothelioma. This virotherapy-immunotherapy combination breaks up cancer cells and injects dendritic cell-activating proteins to stimulate the immune system. ONCOS-102 has a new reported median survival of 22-25 months at the two-year follow-up.
More Survival Stats for Dendritic Cell Therapy
Most of the 29 patients tested had epithelioid cell type mesothelioma, which is the easiest cell type to treat. Only two patients had biphasic cell type mesothelioma and no patients had the sarcomatoid cell type of mesothelioma.
Most patients also received mesothelioma chemotherapy along with dendritic cell therapy.
The survival time ranged from 11 months to 128 months (10 years and 8 months). Most patients survived between 15 and 30 months, which is encouraging.
Ten (10) of the 29 patients eclipsed 30 months. Nine (9) eclipsed 40 months. Nearly 25% — seven (7) out of 29 — eclipsed 50 months.
Four of the 29 patients were still alive at the end of the study’s reporting. Their survival times were:
- 128 months
- 114 months (9 years, 6 months)
- 77 months (6 years, 5 months)
- 71 months (5 years, 11 months)
If you’re interested in dendritic cell therapy or another type of new mesothelioma treatment, contact our team. Registered nurse Karen Ritter can help you find a cancer center with clinical trials. Email her at firstname.lastname@example.org.
Sources & Author
- Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival. Biospace. Retrieved from: https://www.biospace.com/article/releases/targovax-s-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival/. Accessed: 06/14/2021.
- Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158710/. Accessed: 06/14/2021.
Sources & Author